Small Cell Lung Cancer (Limited Stage I–IIA): After Initial Surgery and Adjuvant Therapy Did Not Achieve Disease Response
This protocol addresses patients with small cell lung cancer (SCLC), limited stage, clinical stage I–IIA (T1–2, N0, M0), with pathologically confirmed negative lymph nodes who are operable — and for whom the initial surgical treatment line did not produce a complete or partial disease response on imaging.
Clinical Scenario
Patients in this scenario have SCLC confirmed as clinical stage I–IIA (T1–2, N0, M0) following standard staging evaluation including CT of the chest and upper abdomen, brain imaging, FDG-PET/CT, and lymph node staging. Limited stage is defined as stage I–III (T any, N any, M0) amenable to treatment with definitive radiation doses. Pathologic lymph node staging is negative and the patient is considered operable.
Previous Treatment — Goal Not Reached
The prior treatment line consisted of lobectomy (preferred approach) with mediastinal lymph node dissection or systematic lymph node sampling, followed by adjuvant systemic therapy. The target for that line — complete or partial disease response on imaging after completion of adjuvant therapy — was not achieved. The present protocol defines the next clinical step following that failure.
Next Step — Overview
Subsequent systemic therapy is indicated for eligible patients. Several agent categories are available, with the preferred approach and alternatives determined by individual clinical factors including performance status and prior treatment history. Disease response — complete or partial — is assessed by CT after every 2–3 cycles of systemic therapy. The full structured regimen with preferred agents, sequencing, and alternative options is detailed in the complete protocol.
References
- Patients most likely to benefit from surgery are those with SCLC that is clinical stage I–IIA (T1–2,N0,M0) after standard staging evaluation (including CT of the chest and upper abdomen, brain imaging, FDG-PET/CT imaging, and lymph node staging).
- Limited stage: Stage I-III (T any, N any, M0) that can be safely treated with definitive radiation doses.
- Tarlatamab-dlle (category 1)
- Irinotecan
- Lurbinectedin (if not previously used)
- If prolonged disease free time, re-treatment with platinum-based doublet with or without immunotherapy
- Topotecan Oral (PO) or Intravenous (IV)
- CAV (Cyclophosphamide/Doxorubicin/Vincristine)
- Docetaxel
- Gemcitabine
- Nivolumab or Pembrolizumab (if not previously treated with an ICI)
- Oral Etoposide
- Paclitaxel
- Temozolomide
- The Panel recommends response assessment using CT with contrast of the C/A/P after every 2 to 3 cycles.
View source ↗